3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
2
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
7
Peritoneal Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Colorectal Neoplasms
3
Carcinoma, Transitional Cell
3
Appendiceal Neoplasms
3
Urologic Neoplasms
2
Urogenital Neoplasms
2
Stomach Neoplasms
2
Recurrence
2
Pseudomyxoma Peritonei
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms
2
Anus Neoplasms
2
Uterine Neoplasms
1
Urologic Diseases
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Sarcoma
1
Pleural Neoplasms
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Necrosis
1
Mediastinal Neoplasms
1
Male Urogenital Diseases
1
Gastrointestinal Neoplasms
1
Female Urogenital Diseases
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
3
enfortumab vedotin
2
Mitomycin
2
Gemcitabine
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
relatlimab
1
galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20
1
Ultrasonography
1
Rivaroxaban
1
Ringer's acetate
1
Radiation Dose Hypofractionation
1
Nivolumab
1
Multiparametric Magnetic Resonance Imaging
1
Fluorouracil
1
Cisplatin
1
CP protocol
1
Albumins
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Urologic Neoplasms
×
Mitomycin
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled
NCT05874921
2025-02-28
uTRACT
UroGen Pharma Ltd.
Recruiting
400 enrolled